Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib plus hydroxyurea in recurrent or progressive meningiomas
2008-007988-16Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Dec 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of imatinib and hydroxyurea in meningioma (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Progression-free survival. Started Dec 2008; status: terminated.
02
Drugs
imatinibhydroxyurea
03
Conditions
meningioma
Beyond the preview
Go deeper on 2008-007988-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007988-16.